INTRODUCTION
Several studies have been performed evaluating the significance of a raised troponin in both ischemic heart disease and non-cardiac conditions [1] . While it has been found that cardiac troponins are valuable in the diagnosis of acute coronary syndromes (ACS), it has also been shown to be elevated in other cardiac (e.g., heart failure, myositis) and non-cardiac conditions (e.g., sepsis, renal failure, pulmonary embolism) [2, 3] . The prognosis of patients with nonobstructive coronary artery disease (CAD) is unknown, but recent small studies have found that patients with an elevated troponin level and non-obstructive CAD have an increased risk of death at 1-year follow-up, as well as death and recurrence of myocardial infarction at 2.5 years follow-up [4] [5] [6] , especially noncardiac causes of death [5] . This study was performed to further investigate the outcomes of troponin-positive patients with obstructive and non-obstructive CAD.
METHODS
The analysis in this article does not involve any new studies of human or animal subjects performed by any of the authors. All A retrospective cohort analysis that included all patients who had a raised cardiac troponin T (cTnT; AQT90 FLEX [Radiometer Medical ApS, Brønshøj, Denmark], using the 99th percentile value of 0.017 ng/ml) presenting to Kettering General Hospital (Northamptonshire, UK) between the period of January 2010 to December 2011 was performed. These patients were divided into two groups; the first group comprised patients who underwent coronary angiograms and the second group comprised patients who were too high risk for coronary angiograms and were medically managed. The patients who had angiograms were stratified anatomically, into non-obstructive epicardial CAD with \50% stenosis (NO-CAD) and obstructive epicardial CAD with C50% stenosis (O-CAD). The NO-CAD patients were subgrouped by the cause of raised troponin if this could be identified (NO-CAD-I) versus the group where the cause remained unidentified (NO-CAD-U). Also, the O-CAD cohort was analyzed [7] .
Statistical Methods
The data were analyzed with the use of MedCalc The mean age was equivalent between both groups and there were more female patients in the NO-CAD group when compared with the O-CAD. Comparing for risk factors for CAD showed that the NO-CAD group had a significant preponderance of hypertension (73 patients, 63% vs. 435 patients, 51%, P = 0.0068; Table 1 ).
The NO-CAD group had a trend toward lower level of cTnT elevation (0.5 ± 0.6 vs.
2.4 ± 4.7, P = 0.121) and a longer length of hospital stay (9.1 ± 16.4 vs. 5.3 ± 7.9, P = 0.253). The evaluation of the renal functions showed that the NO-CAD group had more patients with severe renal impairment with a glomerular filtration rate \15 ml/min/ 1.73 m 2 (5 patients, 4.3% vs. 5 patients, 0.5%, P = 0.0014; Table 2 ).
The comparison between the echocardiographic findings showed no structural heart disease by echocardiogram in the NO-CAD group (43 patients, 37% vs. 178 patients, 21%, P\0.0001) and more patients with aortic valve disease and left ventricular hypertrophy ( Table 3 ). Table 4 ].
The subgroup analysis of the NO-CAD group showed that the 35 patients who had no identifiable cause for the cTnT elevation were a low-risk group (MACCE at 1-year = 0). In the NO-CAD group, the most common identified 
DISCUSSION
Previous studies indicated that the detection of the highly specific troponin in blood is an independent risk factor that identifies patients presenting with unstable angina or non-ST (Table 6 ) [9] [10] [11] [12] [13] .
In several studies of ACSs, troponin elevation has been associated with a worse prognosis [9, 14] . However, troponin elevation in the absence of thrombotic ACS still retains the prognostic value [9] . The risk for subsequent death appears to be related to the degree of troponin elevation [8] . There is a significant increase in mortality with increasing levels of troponin, and the RR for death is 7.8 in patients with the high troponin levels compared to those with normal levels [8] . The short-and long-term survival rates are impaired among patients with troponin elevation in many different clinical settings, including congestive heart failure, sepsis, pulmonary disease, acute pulmonary embolism, and renal insufficiency [15] . The reasons for this increase in mortality are currently poorly understood, but may be related to myocardial necrosis with myocyte loss or underlying quiescent CAD [9] . These findings challenge the idea that these are ''false-positive'' troponin elevations and that these patients may be regarded as low risk for subsequent cardiovascular events [16] .
Elevation of troponin in these patients may result from coronary atherothrombosis not evident using standard angiography or from other ischemic and non-ischemic mechanisms [16] . It was also previously shown that the incidental troponin rise was more common in older patients and was associated with a poorer prognosis compared to ACSs [17] . Given this substantially increased risk for adverse [9] . A previous study by Mehta et al. [4] compared patients who had elevated troponin levels and \50% stenosis of any major coronary artery on angiography (n = 83) to patients with negative troponin levels. The patients with elevated troponin and non-obstructiveepicardial CAD had an increased incidence of death and recurrence of myocardial infarction at 2.5 years follow-up [4] .
The current study compared patients with elevated cTnT with non-obstructive CAD versus obstructive epicardial CAD. The MACCE rate was similar at 30 days and 1-year follow-up. The mortality rate at 30 days follow-up for the nonobstructive CAD was 5.2% vs. 4.6% in the highrisk obstructive CAD group with a RR (95% CI) of 1.24 (0.54-2.86) (P = 0.61). The rate of mortality at 1-year follow-up was 10.4% vs.
11.2% with a RR (95% CI) of 0.93 (0.53-1.64) (P = 0.8). This was similar to the results of the previous sub-study of the ACUITY trial, which showed that the patients with non-ST elevation ACS and elevated troponin but without obstructive CAD are still at considerable risk for 1-year mortality from cardiac and noncardiac causes [5] . This may be caused by unstable, ruptured plaques, but with no significant coronary lesions by angiography.
A small study by Ohlmann et al. [18] evaluated patients who had intravascular Table 6 Causes of raised troponin
• Chronic or acute renal dysfunction
• Severe congestive heart failure-acute and chronic
• Hypertensive crisis
• Tachy-or brady-arrhythmias
• Pulmonary embolism, severe pulmonary hypertension
• Inflammatory diseases, e.g., myocarditis
• Acute neurological disease, including stroke or subarachnoid hemorrhage
• Aortic dissection, aortic valve disease or hypertrophic cardiomyopathy
• Cardiac contusion, ablation, pacing, cardioversion, or endomyocardial biopsy
• Hypothyroidism
• Apical ballooning syndrome (Takotsubo cardiomyopathy)
• Infiltrative diseases, e.g., amyloidosis, hemochromatosis, sarcoidosis, scleroderma
• Drug toxicity, e.g., adriamycin, 5-fluorouracil, Herceptin, snake venoms [16] ultrasound showing ruptured plaques with no significant angiographic disease. They had a high death rate of 6% and a major adverse cardiac events (MACE) rate of 18% at a mean follow-up of 43 months [18] .
This was also similar to the TACTICS-TIMI-18 sub-study, which followed a total of 895 patients, from which 32 patients had positive troponin and non-obstructive CAD and they were compared to the three other groups for 6-month mortality, re-infarction, or readmission for ACS at 6-month follow-up. This sub-study demonstrated that those patients had an adverse prognosis with no significant difference in outcome between troponinpositive patients with CAD compared with those without CAD (P = 0.20) [16, 19] .
However, this was in contrary to the previous study by Segev et al. [17] which showed that the patients with non-obstructive CAD had a benign clinical outcome compared with those with normal coronary arteries during an intermediate term follow-up of 2.5 years with equal low MACE rate between the two groups.
(1% for both groups; P = 0.9) [17] . Subgroup analysis has not previously been carried out. By sub-grouping the nonobstructive CAD group, we have shown that patients in the non-obstructive CAD group with no identified cause for the raised troponin were at low risk at 1-year follow-up (MACCE at 1-year = 0). In the non-obstructive CAD group with identified cause, the most common causes of raised troponin were tachyarrhythmia, respiratory failure/severe pneumonia, sepsis and advanced malignancies (Table 6 ). This has been demonstrated in previous studies, with elevation Troponin in many different clinical settings, including congestive heart failure, sepsis, pulmonary disease, acute pulmonary embolism, and renal insufficiency [20] [21] [22] . The mechanism of troponin release is unknown in the absence of flow-limiting CAD, suggesting the presence of mechanisms other than thrombotic coronary artery occlusion, probably a transient loss in membrane integrity with subsequent troponin leakage or micro-vascular thrombotic injury [23] .
Further comparison of this non-obstructive CAD group with identified cause to the obstructive CAD management subgroups demonstrated that these patients had higher 1-year MACCE rate and overall mortality compared with the emergency revascularized group. This increased mortality was driven by higher risk of non-cardiac death [RR (95% CI) = 4.10 (1.53-10.99), P = 0.005; Fig. 2 ).
CONCLUSION
Patients with a raised troponin and nonobstructive CAD with an identified cause are at equivalent risk of MACCE and death at 30 days and 1-year follow-up compared to those with obstructive CAD. Patients in the non-obstructive CAD group were at a similar risk whether managed with urgent or delayed revascularization or medical therapy for obstructive CAD, with the best outcomes seen in the emergency revascularization group. This finding challenges the prevailing perception that these patients form a low-risk group.
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